Autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma: a retrospective study / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 617-622, 2013.
Article
in Zh
| WPRIM
| ID: wpr-332725
Responsible library:
WPRO
ABSTRACT
The purpose of this study was to investigate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL), and analyse the factors influencing prognosis. The clinical data of 67 patients with DLBCL received auto-HSCT from 1996 to 2011 and cumulative overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and relapse rate were retrospectively analyzed. The results showed that the median follow-up time was 40 months after transplantation. Three-year cumulative OS and PFS were 70.6% and 66.4% respectively, 5-year cumulative OS and PFS were 70.6% and 63.8% respectively, and TRM was 7.2%. One-year and three-year cumulative relapse rate were 16.5% and 23.7% respectively. Univariate analysis revealed that the age and pre-transplant disease status were significantly associated with poor prognosis (P < 0.05). It is concluded that auto-HSCT is a safe and effective therapeutic option for patients with DLBCL, especially for the young patients or patients with better remission.
Full text:
1
Index:
WPRIM
Main subject:
Prognosis
/
Therapeutics
/
Transplantation, Autologous
/
Survival Rate
/
Retrospective Studies
/
Mortality
/
Lymphoma, Large B-Cell, Diffuse
/
Treatment Outcome
/
Hematopoietic Stem Cell Transplantation
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2013
Type:
Article